TPA
REGN icon

Trivium Point Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Trivium Point Advisory’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-336
Closed -$270K – 349
2024
Q3 		$270K Buy
336
+127
+61% +$141K 0.04% 294
2024
Q2 		$220K Buy
+209
New +$203K 0.03% 286

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Trivium Point Advisory's REGN Position: Q4 2024 in Review

Trivium Point Advisory sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 336 shares — an estimated $270K sold.

Trivium Point Advisory first reported a position in REGN in Q2 2024 and held it in 2 quarters. The position peaked at $270K in Q3 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Trivium Point Advisory reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Trivium Point Advisory sold 336 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $270K.
  • Trivium Point Advisory first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Trivium Point Advisory's Regeneron Pharmaceuticals position peaked at $270K in Q3 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Trivium Point Advisory's 13F filing for Q4 2024, filed 13 Feb 2025.